Vita 34 AG Achieves Strongest Growth Since 2010
. - Revenues increase by 15 percent as compared to prior year to EUR 16.3 million - Profitability significantly increase…
. - Revenues increase by 15 percent as compared to prior year to EUR 16.3 million - Profitability significantly increase…
Vita 34 AG (WKN A0BL84), a pioneer in the field of the storage of stem cells from umbilical cord blood and tissue and a…
. Revenues increased by 16.9 percent to EUR 12.0 million EBIDTA rose in annual comparison after rapid integration succ…
Revenue increased by 25 percent as compared with the same period last year Promising growth markets opened thanks to new…
Vita 34 improves total operating revenue by about 22 percent to EUR 18.5 million compared to previous year Clearly incre…
. - Total operating revenue increased by 4.9 percent from last year to EUR 11.4 million - Earnings before interest, ta…
Vita 34 AG (WKN A0BL84), the largest private stem cell bank in the Germanspeaking countries, announces preliminary, unau…
. - Earnings before interest, taxes, depreciation and amortization (EBITDA) rises to EUR 1.5 million; high EBITDA margi…
. - Unique characteristic: Vita 34 is the only company in Germany that can store umbilical cord tissue along with umbil…
. - Presence of capital stock totaled 32.78%. - Management Board reported on fiscal year 2012 and confirmed positive o…